STOCK TITAN
  1. Home
  2. News
  3. ZYNE

Zynerba Pharmaceuticals Inc - ZYNE STOCK NEWS

Welcome to our dedicated news page for Zynerba Pharmaceuticals (Ticker: ZYNE), a resource for investors and traders seeking the latest updates and insights on Zynerba Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zynerba Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zynerba Pharmaceuticals's position in the market.

News
HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE
Rhea-AI Summary
Harmony Biosciences completes acquisition of Zynerba Pharmaceuticals, expanding its portfolio with Zygel
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.87%
Tags
acquisition
-
News
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions
Rhea-AI Summary
Zynerba Pharmaceuticals reminds stockholders to tender their shares into the offer by Harmony Biosciences Holdings to purchase all outstanding shares of Zynerba common stock. The tender deadline is October 10, 2023, and stockholders will receive an up-front purchase price of $1.1059 per share plus one non-tradeable contingent value right per share. If all milestones are achieved, the total consideration payable to stockholders is up to $3.6503 per share in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.31%
Tags
none
-
News
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
Rhea-AI Summary
Zynerba Pharmaceuticals urges stockholders to tender their shares in response to the pending tender offer by Harmony Biosciences Holdings. Harmony is offering an up-front purchase price of $1.1059 per share plus one non-tradable contingent value right (CVR) per share. The maximum additional payment to shareholders is up to an additional approximately $2.5444 per share in cash. The Offer is conditioned upon more than 50% of the outstanding shares of Zynerba common stock being tendered. As of September 27, approximately 32.1% of Zynerba's outstanding shares of common stock were tendered. The Offer has been extended until October 10, 2023. The Zynerba Board unanimously recommends that Zynerba stockholders tender their shares pursuant to the Offer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
none
News
HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
Rhea-AI Summary
Harmony Biosciences Holdings, Inc. extends tender offer for Zynerba Pharmaceuticals, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
acquisition
-
News
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium
Rhea-AI Summary
Zygel (ZYN002) achieved statistically significant and clinically meaningful improvements in multiple efficacy assessments in a Phase 2 trial for children and adolescents with 22q11.2 deletion syndrome. The treatment showed positive results in anxiety-related and other behavioral symptoms, with statistically significant improvements in various scales. Caregivers reported improvement in self-identified problems. Zygel was generally well-tolerated with mild adverse events. Further study is warranted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
clinical trial
-
News
HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
Rhea-AI Summary
Harmony Biosciences announces agreement to acquire Zynerba Pharmaceuticals for $60 million in cash, with potential additional payments of up to $140 million based on milestones. Acquisition aims to develop treatment for Fragile X syndrome and other rare neuropsychiatric disorders. Zygel, Zynerba's lead asset, is currently being evaluated in a pivotal Phase 3 clinical trial for FXS. Transaction expected to close by Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
acquisition
News
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.47%
Tags
none
-
News
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
none
-
News
Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
none
News
Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
conferences
Stock ZYNE logo
Zynerba Pharmaceuticals Inc

Nasdaq:ZYNE

ZYNE Rankings

N/A Ranked by Market Cap
#200 Ranked by Stock Gains
N/A Ranked by Dividends

ZYNE Stock Data

70.12M
35.45M
6.07%
12.13%
0.78%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Devon

About ZYNE

at zynerba pharmaceuticals (nasdaq: zyne), we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with significant unmet medical needs. our mission is to improve the lives of patients battling severe health conditions including refractory epilepsy, osteoarthritis, fragile x syndrome, fibromyalgia and peripheral neuropathic pain through these therapeutics. our development pipeline includes patent-protected synthetic transdermal cannabinoid products, cbd gel – zyn002 and thc pro-drug patch – zyn001, which we believe will provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.